Stryker Names Insider Spencer Stiles to Succeed Kevin Lobo

Stryker named its next chief executive on Tuesday, and the board did not look outside the building. Spencer Stiles, the medical device maker's president and chief operating officer, will become CEO on Jan. 1, 2027. Kevin Lobo, CEO since October 2012 and board chair since July 2014, will move to executive chair on the same day. Stryker disclosed the change in a press release distributed on GlobeNewswire at 8:00 a.m. ET on Oct. 6 and in a Form 8-K filed with the SEC minutes later.

The board framed it as a planned handoff. "This announcement is the culmination of a comprehensive, long-term succession planning process," Sheri McCoy, Stryker's lead independent director, said in the release. Lobo said "now is the right time for this leadership transition."

Nine Months in the No. 2 Chair

The clearest tell came in January, when Stiles became president and COO. Before that he had been group president of orthopaedics since 2019, according to the 8-K, which lists him as 50 years old with a 27-year career at the company. The release says he joined Stryker's Endoscopy business in 1999 and has since held leadership roles across Orthopaedics, MedSurg and Neurotechnology. He also led the Wright Medical acquisition and the separation of the spinal implants business.

A Stryker profile of Stiles released with the announcement says he oversaw an orthopaedics group of more than $9 billion and executed more than $9 billion in M&A transactions that generated more than $1.5 billion in new revenue. As COO, the same document says, he oversees a portfolio of more than $25 billion along with enterprise strategy and M&A.

Why Lobo Keeps the Gavel

The board stopped short of a clean split between the top two jobs. Lobo keeps the chair, now in an executive capacity, and Stiles joins the board as its 11th director when the board grows from 10 seats, per the filing. The 8-K adds that Stiles has not been named to any board committee. McCoy signed both executives' letter agreements, dated Oct. 5, as lead independent director.

That is a middle path. TradeFlock has examined why Fortune 500 boards are splitting the chair and CEO roles, and an executive chair keeps the outgoing chief close to the agenda. The letter confirming Lobo's new role, filed as Exhibit 10.1, sets no end date for it. On the same morning, NeoGenomics said its president and COO, Warren Stone, will become CEO on Jan. 4, 2027, while CEO Tony Zook becomes executive chair and Michael Kelly becomes lead independent director, according to a Business Wire release carried by BioSpace.

What the Pay Letters Reveal

The pay letters show where the weight sits for now. Lobo's base salary stays at $1,550,000 and his bonus target at $2,325,000 as executive chair, according to Exhibit 10.1. Stiles' base salary rises to $1,320,000 on Jan. 1, with a bonus target of $1,980,000, or 150% of salary, under Exhibit 10.2. The incoming CEO's base pay will sit $230,000 below his executive chair's.

Equity points the other way. Lobo will not be eligible for new stock awards while he serves as executive chair. Stiles is in line for a recommended February 2027 grant of about $14.2 million, made up of 60% performance stock units and 40% stock options. The options vest over five years, and the performance units pay out only if preset goals are met over a three-year cycle. The board is putting the new CEO's upside in long-dated stock, not salary.

A $26 Billion Company Built on Deals

Stiles inherits a far larger business than Lobo did. Stryker says annual net sales tripled from $8.7 billion in 2012 to more than $26 billion in 2026, and that Lobo completed more than 60 acquisitions, including Mako, the robotic-arm system that reshaped its joint replacement business. In a companion profile of Lobo, Stryker says organic sales growth rose from 4% in 2012 to 10% in 2025 and puts total shareholder return over his tenure at 450%. Those are the company's own figures. The profile also lists the 2025 deal for Inari Medical, which added a peripheral vascular platform.

If Stryker's reported 10% organic growth for 2025 holds, a new CEO has little room to coast.

The Quarter Before the Keys

For now, Lobo remains CEO through Dec. 31, per the 8-K, and Stiles spends the rest of 2026 as CEO-designate. His stated plan, in the release, is to keep "executing our strategy, driving growth and advancing our mission to make healthcare better." That is a continuity pledge, and it matches what the board bought: a quarter of overlap and an executive chair with no exit date. Boards are answering the structure question differently this season, as TradeFlock's coverage of last week's leadership change at Mattel, Paramount's co-CEO pick and Activation Capital's board chair succession showed. At Stryker, the real signal will come next year, in who speaks for the company when the hard calls arrive.

Cover photo: Surgical instruments on a tray, by César Badilla Miranda on Unsplash, used under the Unsplash License.